Respiratory syncytial virus, a drug to protect children

EMA’s CHMP, the European Agency’s Committee for Medicinal Products for Human Use, recommends approval of Nirsevimab for the prevention of respiratory syncytial virus (RSV) in all newborns and infants. It is a monoclonal antibody, which with a single administration is intended to protect the little ones against the most severe clinical manifestations of the virus.